About this trial
Over the past 10 years, electronic cigarettes (e-cigarettes, EC) have been commercialized as a "less harmful" alternative to traditional cigarettes.1,2 However, e-cigarettes are believed to cause pulmonary epithelial, endothelial and vascular dysfunction, and to cause murine phenotypes similar to those of human COPD. Recently, "spiked" vape juice has been linked to severe lung damage. Unfortunately, the effects of e-cigarettes on the human lungs are still poorly understood, especially in healthy young adults. Therefore, establishing the health effects of e-cigarettes in humans is of paramount importance to guide medical and regulatory decision making. Its widespread use and immense popularity among teenagers and young adults have caused major concern given potentially significant addictive and detrimental long-term health effects.
Eligibility criteria
Qualifiers
Male and female subjects 21-30 years of age
At baseline health with no recent illnesses or medical conditions that would preclude enrollment as assessed by the Principal Investigator
Ability to understand a written informed consent form and comply with the requirements of the study.
E-cigarette use for more than 6 months preceding the date of enrollment and less than a 5 pack year smoking history (e-cigarette users) OR less than a 5 pack year smoking history (non-smoker group).
Disqualifiers
History of any lung disease
Control (non-smoking) group: History of illegal drug use by inhalation
History of CNS disease including stroke and dementia, end-stage liver disease, coronary artery disease, renal failure
Acute infection of any kind in the previous 6 weeks
Trial design
Treatments tested in this trial
- Hyperpolarized Xenon -129 MRI
Treatment groups
Sponsors and collaborators
University of Virginia
Lead sponsor
Duke University
Collaborator